RXDX
Closed
Prometheus Biosciences Inc
199.92
+0.18 (+0.09%)
Last Update: 16 Jun 2023 16:30:00
Yesterday: 199.74
Day's Range: 199.92 - 199.92
Send
sign up or login to leave a comment!
When Written:
113.76
Prometheus Biosciences Inc is a biopharmaceutical company that develops and commercializes precision therapies and diagnostic tools for patients with inflammatory bowel disease (IBD). The company was founded in 2016 and is headquartered in San Diego, California.
Prometheus Biosciences' lead product candidate is PR600, a precision therapy for ulcerative colitis and Crohn's disease. The company also has a proprietary diagnostic platform, Prometheus360, which uses molecular and clinical data to personalize treatment for IBD patients.
In addition to its IBD focus, Prometheus Biosciences is also exploring precision therapies for other autoimmune diseases, including lupus and rheumatoid arthritis.
The company has partnerships with several pharmaceutical companies, including Takeda Pharmaceutical Company and Nestle Health Science. As of 2021, Prometheus Biosciences has raised over $400 million in funding from investors such as ARCH Venture Partners, GV, and Sequoia Capital.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Prometheus Biosciences' lead product candidate is PR600, a precision therapy for ulcerative colitis and Crohn's disease. The company also has a proprietary diagnostic platform, Prometheus360, which uses molecular and clinical data to personalize treatment for IBD patients.
In addition to its IBD focus, Prometheus Biosciences is also exploring precision therapies for other autoimmune diseases, including lupus and rheumatoid arthritis.
The company has partnerships with several pharmaceutical companies, including Takeda Pharmaceutical Company and Nestle Health Science. As of 2021, Prometheus Biosciences has raised over $400 million in funding from investors such as ARCH Venture Partners, GV, and Sequoia Capital.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








